cyrilzakka/clinical-trials huggingface dataset:
Dynamic SAX vs Conventional LAX in Internal Jugular Vein Catheterization

Conventionally, short-axis out-of-plane (SAX) or long-axis in-plane (LAX) ultrasound views are commonly used to guide internal jugular vein catheterization.

SAX dynamic needle tip positioning (SAX-DNTP) is a novel ultrasound imaging technique that enables continuous visualization of the needle tip during ultrasound-guided cannulation; When the needle tip is imaged as a hyperechoic dot, the ultrasound probe is moved a few millimeters, and then the needle is advanced until the needle tip reappears in the vessel lumen. The process is repeated until the needle is advanced more than 1 cm into the lumen. The catheter is then introduced into the vessel.

The aim of this study was to compare the first pass success rate of internal jugular vein catheterization between SAX-DNTP and the conventional LAX technique.


Eligibility Criteria:
Inclusion Criteria:

* Elective cardiac surgery where central venous catheterization is required.

Exclusion Criteria:

* skin infection or trauma
* Shock
* Patients on ECMO or IABP support
* Morbid obesity
* Profound coagulopathy
A Multifaceted Intervention to Improve Hand Hygiene

This randomized controlled trial will evaluate the effect of a multifaceted intervention including performance feedback on adherence to hand hygiene among healthcare workers. A key component of the study is to demonstrate whether improved adherence to hand hygiene leads to a reduction in rates of infection.

A cluster randomized controlled trial of the intervention will be conducted where hospital units (wards) in three hospitals will be allocated to either the intervention or usual practise. We will stratify by hospital site in order to minimize confounding by hospital-level factors. The unit of allocation, intervention, and analysis will be at the level of the hospital unit. Thirty hospital units will be randomized to either the intervention or comparison arm. We will compare adherence to hand hygiene, MRSA rates, and other outcomes between the two study arms.

Eligibility Criteria:
A. Study units Inclusion: Medical and subspecialty units, surgical units, critical care units

Exclusion: pediatric units, neonatal intensive care units

B. Healthcare workers

Inclusion: any hospital staff with direct patient care who are affiliated with a single unit (includes registered nurses, nursing assistants, environmental aides, allied health professionals (occupational, physical, and respiratory therapists), and some physicians

C. Patients Clinical outcomes will be measured in patients on study units.
Evaluation of Skin Affix in the Emergency Room

Effectiveness of a surgical adhesive on wounds found in Emergency Medicine.

Subjects were approached for recruitment in the ED when discussing closure options by the physician. Only subjects deemed appropriate for skin glue closures by their treating physician were approached.Subjects were followed at 48 hours post-procedure, 5-10 days, and at 14 days following the ED visit.

Eligibility Criteria:
Inclusion Criteria:

* Greater than 5 years of age
* Requires the use of a surgical skin adhesive
* Informed consent signed

Exclusion Criteria:

* Sensitivity to topical adhesive products or formaldehyde
* Hx keloid formation, hypotension, diabetes, blood clotting disorders
* Wound infections
* mucosal surfaces or skin exposed to body fluids
Evaluation of the Ovarian Reserve in Infertile Patients With Endometriosis

Comparison between Ovarian reserve markers in patients with minimal/mild endometriosis and patients with tubal factor infertility

Comparison between Ovarian reserve markers (laboratory or us) in patients with minimal/mild endometriosis and patients with tubal factor infertility including:

Cycle Day 2 or 3 FSH and E2, Serum AMH and antral follicular count

Eligibility Criteria:
Inclusion Criteria:

Age 18-35 years of age. Written and signed informed consent by the patient to participate in the study. Patients with regular menses, both ovaries, serum TSH within normal range, body mass index (BMI) \<30 kg/m2 with normal sperm analysis of the husband.

Exclusion Criteria:

Patients with previous endocrine disorders. Cases in which the cause for infertility was other than endometriosis (except for patients with tubal obstruction, in the control group).

Patient with previous surgery for endometriosis.
Effects of a Hybrid Model of Cardiac Rehabilitation on Patient Outcomes

Determine if the standard of care at a cardiac rehabilitation center using what the investigators term to be "hybrid model" on the exercise component of cardiac rehabilitation is associated with improved adherence and outcomes. Discuss the hybrid model in comparison to traditional cardiac rehabilitation and layout a template on how to incorporate this hybrid model. Discuss factors that may lead to poor adherence and attendance to cardiac rehabilitation.

Purpose: The aim of this prospective cohort study was to determine the effectiveness of an individualized physical therapist (PT) driven hybrid model of the exercise component of cardiac rehabilitation (CR) that uses a novel intensity-recovery progression protocol (IRPP) and cardiac testing template (CTT) to assess achieved heart rate intensity (AHRI%), heart rate recovery (HRR%), and intensity-recovery total (IR%) as indicators to guide treatment.

Methods: Assessment of a subjective questionnaire, vital signs, treadmill 6-minute walk (6MW), 1-minute sit-to-stand (1STS), 1-minute step (1ST), and 1-minute agility square tests (1AST) were assessed on 100 participants during the 36-visit program. The hybrid model was led by a PT, was longer in duration, added high intensity interval training (HIIT) to continuous aerobic exercise training (CAET) and resistance training, and used a 1:1 treatment ratio. Treatment intensity and progression were measured based on clinical decision making through the IRPP and CTT.

Eligibility Criteria:
Inclusion Criteria:

* Underwent cardiac surgery (CABG, PCI with stent placement, and valve replacement)
* Surgery was within the previous 365 days
* Could independently ambulate into the facility.

Exclusion Criteria:

* Implantable cardioverter defibrillator (ICD)
* Pacemaker (PPM)
* Heart Transplant
* Left ventricular assist device (LVAD)
* All other cardiac procedures not listed within inclusion criteria
* Diagnosed a-fib
* Participants who attended cardiac rehabilitation before
Edible Seaweeds and Health: Quality Biomarkers to Support Consumer Acceptance

Seaweeds have been part of the diet of Asian countries for thousands of years, but consumption by Quebecers remains unfamiliar. Because of their rich nutrients content and unique bioactive compounds, seaweeds have a great dietary potential. The overall objective of the project is to determine the potential for sustainable local exploitation of St. Lawrence seaweeds by assessing their quality under growing conditions and following processing, and to use them as a basis for culinary innovations for both industry and consumers. Our specific objectives are as follows:

1. To assess the impact of environmental factors on the specific profile of biomarkers of nutritional quality and health potential of harvested or cultivated seaweed;
2. To determine the impact of processing on the profile of biomarkers of nutritional quality and health potential of harvested and cultivated seaweed;
3. To study changes in dietary attitudes and behaviours through a culinary workshop promoting the acceptance of seaweeds and their appropriation as an ingredient by consumers.

The application for ethical approval and this trial registration applies only to Specific Objective 3.

For recruitment purposes, adults interested in cooking and consuming Quebec seaweeds will be randomly assigned to an experimental group (n=16 x 3 groups, ingredients, recipes and a culinary workshop) or a control group (n=16 x 3 groups, ingredients and recipes). Online questionnaires will be administered via the secure platform of INAF (FANI) at the beginning and the end of the study.

Eligibility Criteria:
Inclusion Criteria:

* be interested in cooking and consuming Quebec seaweeds in various forms
* be available to fill out online questionnaires and perhaps participate in a culinary workshop in Quebec City

Exclusion Criteria:

* have allergies and dietary restrictions
Artificial Intelligence Versus Human-controlled Doctor in Virtual Reality Simulation for Sepsis Team Training

The purpose of the study is to compare the effectiveness of Artificial Intelligence virtual doctor with human-controlled virtual doctor avatars on nursing students' sepsis care and interprofessional communication.


Eligibility Criteria:
Inclusion Criteria:

1. All Year 3 NUS nursing students in Academic Year 2022
2. Individuals 20 years old and above; and
3. Consent to be video and/or audio-recorded

Exclusion Criteria:

1. Year 1, 2 and 4 NUS nursing students;
2. Incapable of giving informed consent;
3. Unable to understand and/or speak in English language;
4. Have visual, speech, and/or hearing impairment; and
5. Do not agree to be video and/or audio-recorded.
Prebiotic Effects on Glucose Tolerance

The primary purpose of this project is to evaluate effects in healthy humans on glucose tolerance of cereal products with high amounts of fermentable dietary fibre. Secondary issues are to investigate effects of the test foods on subjective appetite variables, mood variables and gut microbiota composition. The test food products will be consumed in the evening and test variables will be determined the next morning. The study will apply a randomized crossover study design.


Eligibility Criteria:
Inclusion Criteria:

* BMI 18.5 - 25 kg/m2
* age 20-40 years
* normal diet
* healthy

Exclusion Criteria:

* fasting blood glucose \>6.1
* diagnosed or known disease
* known gastrointestinal disorder
* food allergies or intolerance
* special diet regiments
* smokers
Determination of Fractional Flow Reserve by Anatomic Computed Tomographic Angiography

This is a prospective, multi-center trial conducted at up to 20 US, Canadian, European and Asian centers designed to determine the diagnostic performance of CT-FLOW (the investigational technology) by coronary computed tomographic angiography (CCTA) for non-invasive assessment of the hemodynamic significance of coronary lesions, as compared to direct measurement of fractional flow reserve (FFR) during cardiac catheterization as a reference standard.

285 patient, prospective, multi-center trial conducted at up to 20 US, Canadian, European and Asian centers designed to determine the diagnostic performance of CT-FLOW (the investigational technology) by coronary computed tomographic angiography (CCTA) for non-invasive assessment of the hemodynamic significance of coronary lesions, as compared to direct measurement of fractional flow reserve (FFR) during cardiac catheterization as a reference standard

Eligibility Criteria:
Inclusion Criteria:

* Age \>18 years
* Patients providing written informed consent
* Scheduled to undergo clinically-indicated non-emergent invasive coronary angiography (ICA)
* Has undergone \>64 multidetector row CCTA within 60 days prior to ICA
* No cardiac interventional therapy between the CCTA and ICA

Exclusion Criteria:

* Prior coronary artery bypass graft (CABG) surgery
* Prior percutaneous coronary intervention (PCI) for which suspected coronary artery lesion(s) are within a stented coronary vessel
* Contraindication to adenosine, including 2nd or 3rd degree heart block; sick sinus syndrome; long QT syndrome; severe hypotension, severe asthma, , severe COPD or bronchodilator-dependent COPD
* Suspicion of acute coronary syndrome (acute myocardial infarction and unstable angina)
* Recent prior myocardial infarction within 40 days of ICA
* Known complex congenital heart disease
* Prior pacemaker or internal defibrillator lead implantation
* Prosthetic heart valve
* Significant arrhythmia or tachycardia
* Impaired chronic renal function (serum creatinine \>1.5 mg/dl
* Patients with known anaphylactic allergy to iodinated contrast
* Pregnancy or unknown pregnancy status
* Body mass index \>35
* Patient requires an emergent procedure
* Evidence of ongoing or active clinical instability, including acute chest pain (sudden onset), cardiogenic shock, unstable blood pressure with systolic blood pressure \<90 mmHg, and severe congestive heart failure (NYHA III or IV) or acute pulmonary edema
* Any active, serious, life-threatening disease with a life expectancy of less than 2 months
* Inability to comply with study procedures
Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and Paclitaxel

RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This research study is looking at blood and tissue samples from patients with locally advanced, metastatic, or recurrent non-small cell lung cancer treated with bevacizumab, carboplatin, and paclitaxel.

OBJECTIVES:

Primary

* To determine whether germline polymorphisms (DNA) of genes involved in DNA repair (e.g., XPD, ERCC-1, and others) and angiogenesis (e.g., vascular endothelial growth factor \[VEGF\], interleukin-8, CXCR2, adrenomedullin, leptin, and others) are associated with toxicity and clinical outcome in patients with non-small cell lung cancer enrolled on protocol ECOG-4599.

OUTLINE: Blood samples previously obtained from patients on protocol ECOG-4599 are analyzed for the association of germline variations of genes involved in DNA repair (XPD and ERCC1), angiogenesis (VEGF and IL-8), and clinical outcome (overall survival, response, progression-free survival, and toxicity).

Tumor cells are collected from paraffin-embedded tissue using laser-capture microdissection and normal tissue is collected from the specimen. Polymorphisms in ERCC-1, XRCC-1, XRCC-3, GST-P1, TGF-β, and IL-8CXCR are assessed using Taqman assays.

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Available serum or plasma samples from patients with locally advanced, metastatic, or recurrent non-squamous non-small cell lung cancer

  * Stage IIIB (with pleural effusion) or stage IV disease
* Enrolled on protocol ECOG-4599

  * Treated with carboplatin and paclitaxel with or without bevacizumab

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* No prior chemotherapy
Effects of Instrumental and Manipulative Techniques for the Suboccipital Region in Subjects With Chronic Mechanical Neck Pain

The aim of the study is to compare the effectiveness between the suboccipital inhibition technique, the suboccipital inhibition carried out with the INYBI instrument and the suboccipital inhibition with the INYBI plus the upper cervical manipulation, all in patients with chronic mechanic cervicalgia, and to determine which of these techniques is the most effective in the variables studied. In order to do so, 96 subjects participated in the study, being assigned to the 3 intervention groups. We expected the combined treatment (INYBI instrument + upper cervical manipulation) to be the one to produce the best results.


Eligibility Criteria:
Inclusion Criteria:

* Participants aged between 18 and 40 all diagnosed with chronic mechanic cervical pain with an evolution of at least 3 months and who show pain that increases with maintained postures, during movement and during spinal muscles palpation.

Exclusion Criteria:

* participants that can't read and/or fill in the informed consent, either due to a language and/or cognition alteration or age-related factors.
* subjects with psychological pathologies, such as hysteria, depression or anxiety.
* subjects that have received a manual treatment two months before the beginning of the clinical trial.
* subjects who have been recommended by a physician or an anesthetist to receive any type of analgesic, anti-inflammatory or neuromodulator medication, such as antidepressants, antiepileptics and benzodiazepines. If the patient took in this type of medication in an occasional way 72 hours before the beginning of the study, he/she could participate.
* the treatment and assessment techniques will be avoided if: fear to vertebral manipulation in the upper cervical area or positive Klein test and other integrity test of the vertebral artery, positive cervical instability test and positive Spurling test (foraminal compression test).
Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes.

The aim of this prospective, non-randomised, open-label, clinical trial is to compare the effects of two pituitary suppression regimens; GnRH Agonist-Long Protocol and GnRH Antagonist-Flexible Protocol on clinical and embryological IVF/ICSI outcomes, and on the follicular fluid levels of Placental Growth Factor (PlGF); which is known for his pivotal role in the regulation of ovulation, embryo development, and implantation.


Eligibility Criteria:
Inclusion Criteria:

* Women undergoing IVF/ICSI.
* Age: 18-39 years.
* Both ovaries present.

Exclusion Criteria:

* Age ≥ 40 years.
* History of three or more previous IVF failures.
* Patients with hormonal disorders like hyperprolactinemia, thyroid disorders.
* Patients with Polycystic ovary syndrome.
* Patients who previously undergo Unilateral Oophorectomy.
* Patients with chronic diseases: diabetes mellitus, cardiovascular diseases, liver diseases, kidney diseases.
* Patients with diseases may affect IVF outcomes: Endometriosis, uterine fibroids, Hydrosalpinx, Adenomyosis, autoimmune diseases,
* Cancer.
Experiences of Healthcare for Autistic TGD Adults

To explore the experiences of autistic gender diverse adults that have attempted or are attempting to access, have accessed or are currently accessing gender identity healthcare in the United Kingdom


Eligibility Criteria:
Inclusion Criteria:

* Participants must be 18 years or older, they must have first-hand experiences of currently accessing, previously having accessed, or having attempted to access NHS Gender identity clinics in the United Kingdom. The participant must identify as TGD in some capacity (e.g. transgender, nonbinary) and have a formal diagnosis of autism. (Proof of formal diagnosis will not be sought, but participants will be asked about information on this. Diagnosis of autism be asked on the demographic questionnaire, along with question on the diagnosis procedure (e.g. service diagnosis, age of diagnosis). The participant must be able to communicate (verbal or written) in the English Language and be able to provide informed consent.

Exclusion Criteria:

* People who do not meet the inclusion criteria will be excluded from the research.
Treatment of Latent Tuberculosis in Socially Marginalised Citizens

An open-label, randomised controlled trial comparing compliance to treatment for latent tuberculosis infection in socially marginalised citizens. Participants will be randomized to either daily isoniazid for 6 months or weekly rifapentine and isoniazid as directly observed therapy for twelve weeks.

Eligible participants will be randomised to receive either daily isoniazid for 6 months with monthly visits for pill count, evaluation of adverse events and dispensing of isoniazid for the next month, or weekly doses of rifapentine and isoniazid for twelve weeks as direct observed therapy where the drugs are administered in the presence of a study nurse or doctor.

Control bloodsamples (ALAT, alkaline phosphatase, bilirubin, INR, haemoglobin, trombocytes and leukocyte differential count) will be taken at baseline and at least once during treatment in the rifapentine and isoniazid group and at least twice in the isoniazid-only group.

One year after treatment completion participants will be called in for evaluation for active tuberculosis.

Eligibility Criteria:
Inclusion Criteria:

* Reporting to be homeless (independent of whether the person has an official address) or regularly seeking homeless shelters or public institutions to supply basic needs
* LTBI defined by positive IGRA test
* Found plausible by study doctor that the person has been exposed to tuberculosis within 2 years
* Aged 18 years or older

Exclusion Criteria:

* Previously treated for tuberculosis
* Pregnant or breastfeeding
* Active tuberculosis (evaluated by chest x-ray and examination by a trained doctor)
* Unable to give informed consent
* Tested positive for LTBI as part of contact investigation where the index case has or is suspected to have INH of RIF resistant TB
* Known HIV on antiretroviral treatment
* Porphyria
* Known allergy to rifamycins or isoniazid
* Known epilepsy
* Known liver disease causing affected liver parameters (ALAT, alkaline phosphatase, bilirubin, INR)
* Any lab abnormality, disease, concomitant medication or condition that, in the opinion of the investigator, excludes a person from participating
GSK372475 Bioequivalence Study

The study is to show the new salt formulation of GSK372475 is equivalent to the old salt formulation of GSK372475.


Eligibility Criteria:
Inclusion Criteria:

* Healthy Males/Females aged 18-45 years
* Non-smokers
* BMI 19-30 kg.m2
* QTc\<450msec

Exclusion Criteria:

* Use of oral contraception
* Positive breath alcohol and drug screen
* Regular alcohol consumption
* Current psychiatric illness or within 1 year.
* History of GI, hepatic or renal disease
* Uncontrolled hypertension
The Aim is to Identify Recurrent Genomic Mutations and/or Predisposing Polymorphisms in Patients With Sporadic Cases of Multiple Myeloma

There is a growing body of data suggesting that the the risk of developing multiple myeloma, or myelomagenesis, is associated with genetic alterations occurring in the tumor cells. A limited number of candidate genes and polymorphisms have been reported in patients with this disease. In this study the investigators will compare the genetic information obtained on purified abnormal plasmocytes obtained from patients with multiple myeloma with available public databases in an effort to identify and if possible validate the role of certain mutations and/or polymorphisms in myelomagenesis. Plasmocytes will be obtained by immunomagnetic enrichment using CD138+ beads.


Eligibility Criteria:
Inclusion Criteria:

* diagnosis of multiple myeloma
* availability of abnormal plasmocytes

Exclusion Criteria:

- none